Target intelligence / Profile preview

Physical adhesion

Molecular classification
Other
01

Overview

Physical adhesion refers to the biological and mechanical process by which cells attach to neighboring cells or the extracellular matrix (ECM). This interaction is primarily mediated by cell adhesion molecules (CAMs), which include four major families: integrins, cadherins, selectins, and the immunoglobulin superfamily (Albelda & Buck, FASEB J, 1990). These proteins facilitate crucial physiological activities such as tissue formation, wound repair, and the recruitment of immune cells to inflammatory sites. In disease states, aberrant physical adhesion plays a central role in cancer metastasis—where cells detach from a primary tumor and adhere to distant sites—and in chronic inflammatory conditions like multiple sclerosis and Crohn's disease, where excessive leukocyte adhesion causes tissue damage (Ley et al., Nat Rev Immunol, 2007). While 'physical adhesion' itself is a process rather than a discrete protein, it is the primary phenomenon targeted by a variety of monoclonal antibodies and small molecules that inhibit specific CAMs to manage inflammation and prevent thrombosis. Therapeutic intervention often focuses on disrupting the physical bond between cells to modulate immune responses or limit the spread of malignant cells.

Other names
Cell adhesionIntercellular adhesionCell-matrix adhesionBiological adhesion
02

Mechanism of action

Competitive or non-competitive inhibition of cell adhesion molecules (e.g., integrins) to prevent ligand binding and subsequent cellular attachment or transmigration.

03

Biological functions

Cell-cell signaling (Gumbiner, Cell, 1996)Tissue morphogenesisLeukocyte extravasation and migration (Ley et al., Nat Rev Immunol, 2007)Wound healingSignal transductionMaintenance of tissue architecture
04

Disease associations

Cancer metastasisInflammationAutoimmune diseaseThrombosisPost-surgical adhesions (fibrous bands)Infection (pathogen attachment)
05

Safety considerations

Increased risk of opportunistic infections (e.g., Progressive Multifocal Leukoencephalopathy)Impaired wound healingIncreased bleeding riskReduced immune surveillance
06

Interacting drugs

Natalizumab

5 more in the full profile.

07

Biomarkers

Soluble Intercellular Adhesion Molecule-1 (sICAM-1)Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1)E-selectinIntegrin beta-7 expression levels

Beyond the preview

Go deeper on Physical adhesion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Physical adhesion.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call